Bavarian Nordic Discloses Share Buyback Transactions Under DKK 250M Program
Bavarian Nordic is repurchasing shares worth up to DKK 250 million between Sept. 1 and Oct. 30, 2026, under EU market-abuse safe-harbor rules.
Bavarian Nordic A/S disclosed transactions carried out under its ongoing share buyback program, the Danish biotechnology company announced Monday from Copenhagen. The repurchase effort, which began September 1, 2026, authorizes the company to buy back its own shares for a total value not exceeding DKK 250 million before the program closes October 30, 2026.
The buyback is being conducted in compliance with Regulation (EU) No. 596/2014, the European Parliament's market abuse regulation, as well as Commission Delegated Regulation (EU) 2016/1052. Together, those two pieces of legislation form the EU's Safe Harbour framework, which sets strict procedural conditions under which companies may repurchase their own shares without triggering insider-trading concerns.
Read more Lotus Tech to Appear at WasabiCard Stablecoin Payments Event →
Share buyback programs of this type are commonly used by publicly traded companies to return capital to shareholders, potentially support the share price, or reduce the total number of outstanding shares. By operating under the Safe Harbour rules, Bavarian Nordic gains legal certainty that its repurchase activity will not be treated as market manipulation by European regulators.
Bavarian Nordic trades on the Nasdaq Copenhagen exchange under the ticker BAVA. The company, best known for its vaccine portfolio including mpox and travel-disease immunizations, has been an active participant in European equity markets. The full transaction detail for the buyback period is expected to be disclosed periodically in line with regulatory requirements.
Continue reading at GlobeNewswire - Industry News on Financial Services.
